Keyphrases
Active Treatment
34%
Affect Responses
42%
Alzheimer's Disease
85%
CHRNA4
42%
CHRNA5
42%
Clinical Care
85%
Concussive
17%
CYP2A6
42%
Cytochrome P450 2D6 (CYP2D6)
42%
Default Mode Network
51%
Dopamine D2 Receptor (DRD2)
42%
Dorsal Anterior Cingulate Cortex (dACC)
51%
Dorsal Attention Network
34%
Dorsolateral Prefrontal
17%
DRD4
42%
Drug-gene Interaction
42%
Efficacy Rate
42%
Genetic Polymorphism
42%
Genetic Testing
42%
Genetic Variation
42%
Improved Outcomes
42%
Inclusion Criteria
42%
Left-handed
34%
Monoaminergic System
85%
Montgomery-asberg Depression Rating Scale
34%
Mood Disorders
85%
N-methyl-D-aspartate Receptor (NMDAR)
85%
Network Correlation
17%
Network Mapping
51%
Network Mode
34%
Network Target
85%
Pathophysiology
100%
Patients with Depression
17%
Pharmacogenetics
85%
Pharmacotherapy
42%
Receptor Function
24%
Repetitive Transcranial Magnetic Stimulation (rTMS)
85%
Resting-state Functional Connectivity (rs-FC)
85%
Resting-state Functional Magnetic Resonance Imaging (rs-fMRI)
17%
Right-sided
51%
Sham
51%
Smokers
42%
Smoking Cessation
85%
Smoking Cessation Intervention
85%
Starting Treatment
17%
Stimulation Site
34%
Traumatic Brain Injury
85%
Treatment Decisions
42%
Treatment Outcome
42%
Treatment-resistant Depression
85%
Neuroscience
Alzheimer's Disease
85%
Anterior Cingulate Cortex
17%
Antidepressant
34%
Biogenic Amine
17%
Bipolar Disorder
17%
CHRNA4
85%
CHRNA5
85%
Cognitive Function
12%
CYP2A6
85%
CYP2B6
85%
Decision-Making
85%
Default Mode Network
51%
Dextro Aspartic Acid
85%
Drug Therapy
85%
Functional Connectivity
17%
Functional Magnetic Resonance Imaging
17%
Genetic Polymorphism
85%
Genetic Variation
85%
Genome-Wide Association Study
12%
Locus Coeruleus
12%
Major Depressive Disorder
17%
Mood Disorder
85%
Mood Stabilizer
17%
Neurodegeneration
12%
Neurotransmitter
17%
Neurotrauma
85%
NMDA Receptor
85%
Raphe Nucleus
12%
Receptor
51%
Receptor Expression
17%
Receptor Modulator
17%
Transcranial Magnetic Stimulation
85%
Traumatic Brain Injury
85%
Treatment-Resistant Depression
85%
